Targeting Bruton's Tyrosine Kinase (BTK) With Ibrutinib After Autologous Stem Cell Transplantation in "Double-Hit" B-Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications B cell lymphoma
- Focus Therapeutic Use
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.
- 20 Apr 2016 Planned primary completion date changed from 1 Jan 2021 to 1 Jul 2021.